[{"data":1,"prerenderedAt":225},["ShallowReactive",2],{"$fzzxqgzwfsz1w":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":59,"top_diseases":83,"top_companies":109,"key_results":133,"trends":212,"previous_editions":221,"comparison":138,"highlighted_classes":222},1,"asco-gi-2026","ASCO GI","asco-gi","ASCO Gastrointestinal Cancers Symposium 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},877,381,109,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 2\u002F3":20,"Phase 3":21},34,29,129,7,47,[23,27,31,35,38,41,45,48,52,56],{"name":24,"count":25,"share":26},"PDCD1",62,16,{"name":28,"count":29,"share":30},"TS",53,14,{"name":32,"count":33,"share":34},"CD274",44,12,{"name":36,"count":37,"share":20},"VEGFR2",28,{"name":39,"count":40,"share":20},"VEGFR4",25,{"name":42,"count":43,"share":44},"TUBB",23,6,{"name":46,"count":47,"share":44},"TOP1",21,{"name":49,"count":50,"share":51},"VEGFR-1",20,5,{"name":53,"count":54,"share":55},"SSTR2",15,4,{"name":57,"count":34,"share":58},"PDGFRA",3,[60,64,68,70,73,76,78,81],{"name":61,"count":62,"share":63},"Small molecules",198,52,{"name":65,"count":66,"share":67},"Monoclonal antibodies",149,39,{"name":69,"count":47,"share":44},"Antibody-drug conjugates",{"name":71,"count":72,"share":51},"Radiopharmaceuticals",19,{"name":74,"count":75,"share":55},"Bispecific antibodies",17,{"name":77,"count":75,"share":55},"Peptides",{"name":79,"count":20,"share":80},"Non-antibody therapeutic proteins",2,{"name":82,"count":51,"share":4},"Carbohydrate, lipid and polymer therapeutics",[84,87,89,91,94,98,100,103,105,107],{"name":85,"count":86,"share":75},"colorectal cancer (CRC)",66,{"name":88,"count":29,"share":30},"metastatic colon cancer (mCRC)",{"name":90,"count":21,"share":34},"gastric cancer (GC)",{"name":92,"count":93,"share":34},"pancreatic adenocarcinoma (PDAC)",46,{"name":95,"count":96,"share":97},"hepatocellular carcinoma (HCC)",40,10,{"name":99,"count":67,"share":97},"gastroesophageal junction adenocarcinoma",{"name":101,"count":102,"share":20},"gastric adenocarcinoma",27,{"name":104,"count":40,"share":20},"pancreatic cancer (PC)",{"name":106,"count":47,"share":44},"Esophageal Squamous Cell Carcinoma (ESCC)",{"name":108,"count":50,"share":51},"biliary cancer",[110,112,115,117,119,121,124,126,129,131],{"name":111,"count":37,"share":20},"AstraZeneca",{"name":113,"count":114,"share":44},"Bristol Myers Squibb",24,{"name":116,"count":50,"share":51},"Genentech",{"name":118,"count":54,"share":55},"Sanofi",{"name":120,"count":30,"share":55},"Taiho Pharmaceutical",{"name":122,"count":123,"share":58},"BeiGene",13,{"name":125,"count":34,"share":58},"Merck",{"name":127,"count":128,"share":58},"Eli Lilly",11,{"name":130,"count":128,"share":58},"HUTCHMED",{"name":132,"count":128,"share":58},"Pfizer",[134,142,148,154,160,167,173,180,187,193,199,205],{"title":135,"drug":136,"company":138,"phase":139,"disease":88,"finding":140,"url":141},"Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6\u002Fbevacizumab\u002Fatezo (FFX\u002Fbev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004\u002FSWOG-S1610.",{"name":137,"slug":137},"atezolizumab",null,"Phase 3","Median PFS was 30.0 and 4.3 months, ORR was 80.6% v 46%, and DCR at 12 months was 62.9% v 32.4% in the FFX\u002Fbev+atezo arm compared to the atezo-only arm, respectively.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.14",{"title":143,"drug":144,"company":125,"phase":139,"disease":95,"finding":146,"url":147},"Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.",{"name":145,"slug":145},"pembrolizumab","Median DMFS was NR (95% CI, 58.7 to NR) with pembrolizumab vs NR (95% CI, 59.0 to NR) with placebo (HR 0.98; 95% CI, 0.77-1.24), with 48 mo DMFS rate of 71% vs 70%.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.477",{"title":149,"drug":150,"company":111,"phase":139,"disease":101,"finding":152,"url":153},"Analysis of 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) administration in MATTERHORN: A randomized, phase 3 study of durvalumab (D) plus FLOT in resectable gastric\u002Fgastroesophageal junction (G\u002FGEJ) adenocarcinoma.",{"name":151,"slug":151},"durvalumab","EFS was improved with D + FLOT vs P + FLOT in pts who completed all FLOT (n=228 vs 243; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.49–0.94), stopped some FLOT (n=63 vs 60; HR, 0.35; 95% CI, 0.16–0.71) or stopped all FLOT (n=183 vs 167; HR, 0.72; 95% CI, 0.55–0.95).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.343",{"title":155,"drug":156,"company":138,"phase":139,"disease":101,"finding":158,"url":159},"Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.",{"name":157,"slug":157},"fruquintinib","The analysis showed that FRU plus paclitaxel had a numerical improvement in PFS compared to RAM plus paclitaxel (HR 0.78, 95% CI 0.58-1.04; p = 0.09), with a statistically significant RMST advantage of 1.18 months at 20 months (95% CI 0.08-2.27; p = 0.024).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.360",{"title":161,"drug":162,"company":164,"phase":139,"disease":99,"finding":165,"url":166},"Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.",{"name":163,"slug":163},"zanidatamab","Jazz Pharmaceuticals","Grade ≥3 treatment-related AEs (TRAEs) occurred in 71.8% of pts with zanidatamab + tislelizumab + CT, 59.0% with zanidatamab + CT, and 59.6% with tras + CT.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.lba285",{"title":168,"drug":169,"company":138,"phase":139,"disease":101,"finding":171,"url":172},"Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial.",{"name":170,"slug":170},"oxaliplatin","The 3 and 5-year disease-free survival were 71.2% (66.5-76.3) and 66.2% (61.2-71.6) in the SOX group, as compared with 65.1% (60.2-70.5) and 55.6% (50.4-61.3) in the S-1 group.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.289",{"title":174,"drug":175,"company":138,"phase":177,"disease":88,"finding":178,"url":179},"Regorafenib combined with trifluridine\u002Ftipiracil versus regorafenib monotherapy in refractory metastatic colorectal cancer (FDZL-REGOT): A randomized phase 2 trial.",{"name":176,"slug":176},"regorafenib","Phase 2","The ORR was 11.0% (6\u002F51) vs. 0 (0\u002F51), and DCR was 66.7% (34\u002F51) vs. 29.4% (15\u002F51) in the combination group and the regorafenib group, separately, in the ITT analysis.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.157",{"title":181,"drug":182,"company":184,"phase":177,"disease":92,"finding":185,"url":186},"Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine\u002Fnab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).",{"name":183,"slug":183},"elraglusib","Actuate Therapeutics","The 1-yr OS rate was 44.1% with elraglusib\u002FGnP vs 22.3% with GnP; the mOS was 10.1 mo with elraglusib\u002FGnP vs 7.2 mo with GnP (HR, 0.62; p=0.01) with approximately 79% events recorded (25.8% of pts on elraglusib\u002FGnP and 10.3% on GnP were censored with the majority at >12 mo OS).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.653",{"title":188,"drug":189,"company":138,"phase":177,"disease":106,"finding":191,"url":192},"Preliminary results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (cCRT) versus cCRT alone as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC): A multicentre, randomised study.",{"name":190,"slug":190},"benmelstobart","pCR rates were 50% (9\u002F18) versus 42% (10\u002F24), and MPR rates were 78% (14\u002F18) versus 63% (15\u002F24), respectively.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.376",{"title":194,"drug":195,"company":138,"phase":177,"disease":90,"finding":197,"url":198},"The primary results of a randomized phase II trial of trifluridine\u002Ftipiracil (FTD\u002FTPI) plus ramucirumab (RAM) versus FTD\u002FTPI for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG 15822G).",{"name":196,"slug":138},"trifluridine + tipiracil","There was no significant difference in ORR (5.4% vs 9.1%, P = 0.489) and DCR (50.0% vs 47.3%, P = 0.850) between both arms.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.357",{"title":200,"drug":201,"company":138,"phase":177,"disease":90,"finding":203,"url":204},"Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial.",{"name":202,"slug":202},"toripalimab","The 3-year EFS was 74.7% (95% CI: 63.6–87.7%) in the toripalimab plus chemotherapy group and 56.2% (95% CI: 43.3–73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.52 (95% CI: 0.27–1.00; P = 0.047).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.282",{"title":206,"drug":207,"company":138,"phase":177,"disease":209,"finding":210,"url":211},"Preliminary results of ALTER-PA-001 trial: A multicenter, open-label, randomized, phase II trial of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer.",{"name":208,"slug":208},"anlotinib","pancreatic cancer (PDAC)","The most common TEAE were white blood cell decreased (51.9% vs. 50.0%), anemia (44.4% vs. 42.9%) and neutrophil count decreased (40.7% vs. 42.9%).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.2_suppl.719",{"summary":213,"bullets":215},[214],"Small molecules were the most frequent modality (52% of drug-linked abstracts). PDCD1 was the most frequent target (16%). Colorectal cancer (CRC) was the most frequent disease (17%).",[216,217,218,219,220],"AstraZeneca had the largest company share (7% of drug-linked abstracts).","Antibody-drug conjugates accounted for 6% of drug-linked abstracts.","Bispecific antibodies accounted for 4% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (39%).","TS was the next most frequent target (14%).",[],[223,224],{"name":69,"count":47,"share":44,"previous_count":138,"previous_share":138,"direction":138},{"name":74,"count":75,"share":55,"previous_count":138,"previous_share":138,"direction":138},1793970603095]